Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892059988> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2892059988 abstract "TPS664 Background: PI3K pathway activation plays a crucial role in mediating endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer. We have shown previously that BKM120 in combination with fulvestrant induced synergistic apoptotic cell death in long-term estrogen deprived ER+ breast cancer (LTED) cell line models, supporting the clinical investigation of this combination in ER+ breast cancer. Methods: The study is composed of the dose escalation cohort (phase IA) and the expansion cohort (phase IB). In phase IA, a standard 3+3 phase I design is employed to determine the maximum tolerated dose (MTD) of the combination of BKM120 and fulvestrant in patients (pts) with ER+ metastatic breast cancer (MBC). In phase IB, an additional 10 pts will be enrolled at the MTD to further examine the toxicity profile and preliminary efficacy of this combination. Steady state concentrations of BKM120 will be analyzed. Postmenopausal women with ER+ MBC and measurable disease per RECIST are eligible. Pts who are currently taking fulvestrant without disease progression are eligible. There is no restriction on the number of prior lines of systemic therapy for metastatic disease in phase IA but < 3 lines is required in phase IB. Treatment consists of fulvestrant 500 mg IM administered monthly on day (d) 1 of each 28-d cycle, following the loading dose of 500 mg on d1 and d15, and BKM120 orally daily on d1-28 of each cycle. The starting dose level (DL) is DL1 (Table). Correlative studies include assessing PI3K pathway abnormalities (loss of PTEN and PIK3CA mutation) on archival tumor specimen, and treatment induced inhibition of PI3K pathway activity (pAKT, pS6, Cyclin D1, subcellular localization of FOXO3a, phosphoproteomics), tumor cell proliferation (Ki67) and apoptosis (cleaved caspase 3 or TUNEL staining) on tumor biopsies collected at baseline and cycle 2 day 1 in consented patients. Enrollment to DL1 is complete and the study is currently enrolling pts to DL2. [Table: see text]" @default.
- W2892059988 created "2018-09-27" @default.
- W2892059988 creator A5000113257 @default.
- W2892059988 creator A5009199118 @default.
- W2892059988 creator A5037696116 @default.
- W2892059988 creator A5057135409 @default.
- W2892059988 date "2012-05-20" @default.
- W2892059988 modified "2023-09-27" @default.
- W2892059988 title "A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer." @default.
- W2892059988 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.tps664" @default.
- W2892059988 hasPublicationYear "2012" @default.
- W2892059988 type Work @default.
- W2892059988 sameAs 2892059988 @default.
- W2892059988 citedByCount "4" @default.
- W2892059988 countsByYear W28920599882013 @default.
- W2892059988 countsByYear W28920599882014 @default.
- W2892059988 countsByYear W28920599882019 @default.
- W2892059988 crossrefType "journal-article" @default.
- W2892059988 hasAuthorship W2892059988A5000113257 @default.
- W2892059988 hasAuthorship W2892059988A5009199118 @default.
- W2892059988 hasAuthorship W2892059988A5037696116 @default.
- W2892059988 hasAuthorship W2892059988A5057135409 @default.
- W2892059988 hasConcept C121608353 @default.
- W2892059988 hasConcept C126322002 @default.
- W2892059988 hasConcept C143998085 @default.
- W2892059988 hasConcept C2775930923 @default.
- W2892059988 hasConcept C2780482068 @default.
- W2892059988 hasConcept C530470458 @default.
- W2892059988 hasConcept C71924100 @default.
- W2892059988 hasConcept C84606932 @default.
- W2892059988 hasConceptScore W2892059988C121608353 @default.
- W2892059988 hasConceptScore W2892059988C126322002 @default.
- W2892059988 hasConceptScore W2892059988C143998085 @default.
- W2892059988 hasConceptScore W2892059988C2775930923 @default.
- W2892059988 hasConceptScore W2892059988C2780482068 @default.
- W2892059988 hasConceptScore W2892059988C530470458 @default.
- W2892059988 hasConceptScore W2892059988C71924100 @default.
- W2892059988 hasConceptScore W2892059988C84606932 @default.
- W2892059988 hasLocation W28920599881 @default.
- W2892059988 hasOpenAccess W2892059988 @default.
- W2892059988 hasPrimaryLocation W28920599881 @default.
- W2892059988 hasRelatedWork W1615617460 @default.
- W2892059988 hasRelatedWork W171548121 @default.
- W2892059988 hasRelatedWork W1972211800 @default.
- W2892059988 hasRelatedWork W2042907362 @default.
- W2892059988 hasRelatedWork W2203191607 @default.
- W2892059988 hasRelatedWork W2262697035 @default.
- W2892059988 hasRelatedWork W2321486562 @default.
- W2892059988 hasRelatedWork W2413654632 @default.
- W2892059988 hasRelatedWork W2480578469 @default.
- W2892059988 hasRelatedWork W2602292204 @default.
- W2892059988 hasRelatedWork W2624499646 @default.
- W2892059988 hasRelatedWork W2695006061 @default.
- W2892059988 hasRelatedWork W2793127233 @default.
- W2892059988 hasRelatedWork W2806201321 @default.
- W2892059988 hasRelatedWork W2888877129 @default.
- W2892059988 hasRelatedWork W2946914634 @default.
- W2892059988 hasRelatedWork W2947067278 @default.
- W2892059988 hasRelatedWork W3011244791 @default.
- W2892059988 hasRelatedWork W3135389008 @default.
- W2892059988 hasRelatedWork W3171075867 @default.
- W2892059988 isParatext "false" @default.
- W2892059988 isRetracted "false" @default.
- W2892059988 magId "2892059988" @default.
- W2892059988 workType "article" @default.